@MYTH©bubu et les 12 comploteurs

21. Ozden S., Huerre M., Riviere J.P., Coffey L.L., Afonso P.V., Mouly V., de Monredon J., Roger J.C., El Amrani M., Yvin J.L., Jaffar M.C., Frenkiel M.P., Sourisseau M., Schwartz O., Butler-Browne G., Desprès P., Gessain A., Ceccaldi P.E. (2007). Human muscle satellite cells as targets of Chikungunya virus infection. PLoS One. 2, e57. https://doi.org/10.1371/journal.pone.0000527

22. Sourisseau M., Schilte C., Casartelli N., Trouillet C., Guivel-Benhassine F., Rudnicka D., Sol-Foulon N., Le Roux K., Prevost M.C., Fsihi H., Frenkiel M.P., Blanchet F., Afonso P.V., Ceccaldi P.E., Ozden S., Gessain A., Schuffenecker I., Verhasselt B., Zamborlini A., Saïb A., Rey F.A., Arenzana-S.F., Desprès P., Michault A., Albert M.L., Schwartz O. (2007). Characterization of reemerging chikungunya virus. PLoS Pathog. 3, e89. https://doi.org/10.1371/journal.ppat.0030089

23. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., Lim A., Osborne C.S., Pawliuk R., Morillon E., Sorensen R., Forster A., Fraser P., Cohen J.I., de Saint Basile G., Alexander I., Wintergerst U., Frebourg T., Aurias A., Stoppa-Lyonnet D., Romana S., Radford-Weiss I., Gross F., Valensi F., Delabesse E., Macintyre E., Sigaux F., Soulier J., Leiva L.E., Wissler M., Prinz C., Rabbitts T.H., Le Deist F., Fischer A., Cavazzana-Calvo M. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 302, 415-419. https://doi.org/10.1126/science.1088547

24. Nowrouzi A., Glimm H., von Kalle C., Schmidt M. (2011). Retroviral vectors : post entry events and genomic alterations. Viruses. 3, 429-455. https://doi.org/10.3390/v3050429

25. Chandler R.J., Sands M.S., Venditti C.P. (2017). Recombinant Adeno-Associated Viral Integration and Genotoxicity : Insights from Animal Models. Hum. Gene Ther. 28, 314-322. https://doi.org/10.1089/hum.2017.009

26. Gil-Farina I., Schmidt M. (2016). Interaction of vectors and parental viruses with the host genome. Curr. Opin. Virol. 21, 35-40. https://doi.org/10.1016/j.coviro.2016.07.004

27. Raper S.E., Chirmule N., Lee F.S., Wivel N.A., Bagg A., Gao G.P., Wilson J.M., Batshaw M.L. (2003). Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80, 148-158. https://doi.org/10.1016/j.ymgme.2003.08.016

28. Goossens M., Pauwels K., Willemarck N., Breyer D. (2013). Environmental risk assessment of clinical trials involving modified vaccinia virus Ankara (MVA)-based vectors. Curr. Gene Ther. 13, 413-420. https://doi.org/10.2174/156652321306140103221941

29. Brehm M., Samaniego L.A., Bonneau R.H., DeLuca N.A., Tevethia S.S. (1999). Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more alpha-genes : ICP4, ICP27, ICP22, and ICP0. Virology. 256, 258-269. https://doi.org/10.1006/viro.1999.9653

30. Ramírez J.C., Gherardi M.M., Esteban M. (2000). Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice : virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J. Virol. 74, 923-933. https://doi.org/10.1128/jvi.74.2.923-933.2000

«  [C]ontrairement à vous seul la vérité et les faits m’intéresse  !  »

Auteur anonyme, première moitié du XXIe siècle

Heil Μπουρλά !